Literature DB >> 8429330

Duration of illness in Huntington's disease is not related to age at onset.

R A Roos1, J Hermans, M Vegter-van der Vlis, G J van Ommen, G W Bruyn.   

Abstract

The age at onset and duration of illness were studied in patients with Huntington's disease in the Leiden Roster which at 1 July 1990 contained 2787 patients. Of 1106 patients, 800 deceased and 306 alive, the age at onset was known. The median duration was 16.2 (range 2-45) years. In contrast to the current opinion, the median duration was independent of the age of onset. The median duration in juvenile Huntington's disease was 17.1 years, which is much longer than reported in the literature, and comparable with the categories for the age of onset of 20-34 and 35-49 years. Only in the group where onset was over 50 years of age was the median duration somewhat shorter (15.6 years), which can be ascribed to unrelated causes of death. As age of onset and duration of illness are not related, at least two mechanisms to determine the clinical course have to be postulated: one for age of onset and another for duration of illness. Duration was shorter for males, especially for those with an affected father.

Entities:  

Mesh:

Year:  1993        PMID: 8429330      PMCID: PMC1014774          DOI: 10.1136/jnnp.56.1.98

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  Clinical and neuropathologic assessment of severity in Huntington's disease.

Authors:  R H Myers; J P Vonsattel; T J Stevens; L A Cupples; E P Richardson; J B Martin; E D Bird
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

2.  The natural history of Huntington disease: possible role of "aging genes".

Authors:  L A Farrer; P M Conneally; P L Yu
Journal:  Am J Med Genet       Date:  1984-05

3.  Progression rate and age at onset are related in autosomal dominant neurologic diseases.

Authors:  R D Currier; J F Jackson; E F Meydrech
Journal:  Neurology       Date:  1982-08       Impact factor: 9.910

4.  Factors associated with slow progression in Huntington's disease.

Authors:  R H Myers; D S Sax; W J Koroshetz; C Mastromauro; L A Cupples; D K Kiely; F K Pettengill; E D Bird
Journal:  Arch Neurol       Date:  1991-08

5.  Age at onset in Huntington's disease: effect of line of inheritance and patient's sex.

Authors:  R A Roos; M Vegter-van der Vlis; J Hermans; H M Elshove; A C Moll; J J van de Kamp; G W Bruyn
Journal:  J Med Genet       Date:  1991-08       Impact factor: 6.318

6.  Juvenile Huntington disease.

Authors:  J G van Dijk; E A van der Velde; R A Roos; G W Bruyn
Journal:  Hum Genet       Date:  1986-07       Impact factor: 4.132

  6 in total
  34 in total

1.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

2.  22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium.

Authors:  Sheharyar S Baig; Mark Strong; Elisabeth Rosser; Nicola V Taverner; Ruth Glew; Zosia Miedzybrodzka; Angus Clarke; David Craufurd; Oliver W Quarrell
Journal:  Eur J Hum Genet       Date:  2016-05-11       Impact factor: 4.246

3.  Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Authors:  Jussi O T Sipilä; Tommi Kauko; Markku Päivärinta; Kari Majamaa
Journal:  J Neurol       Date:  2017-08-28       Impact factor: 4.849

4.  Managing juvenile Huntington's disease.

Authors:  Oliver W J Quarrell; Martha A Nance; Peggy Nopoulos; Jane S Paulsen; Jonathan A Smith; Ferdinando Squitieri
Journal:  Neurodegener Dis Manag       Date:  2013-06-01

5.  Trinucleotide repeat length and progression of illness in Huntington's disease.

Authors:  K Kieburtz; M MacDonald; C Shih; A Feigin; K Steinberg; K Bordwell; C Zimmerman; J Srinidhi; J Sotack; J Gusella
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

Review 6.  Dysphagia in Huntington's disease: a review.

Authors:  Anne-Wil Heemskerk; Raymond A C Roos
Journal:  Dysphagia       Date:  2010-09-14       Impact factor: 3.438

7.  Problems assessing uptake of Huntington disease predictive testing and a proposed solution.

Authors:  Roslyn J Tassicker; Betty Teltscher; M Kaye Trembath; Veronica Collins; Leslie J Sheffield; Edmond Chiu; Lyle Gurrin; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2008-07-30       Impact factor: 4.246

8.  Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease.

Authors:  Brooke R Snyder; Andrew M Chiu; Darwin J Prockop; Anthony W S Chan
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

9.  Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Leigh J Beglinger; Kevin Duff; Jessica Allison; Danielle Theriault; Justin J F O'Rourke; Anne Leserman; Jane S Paulsen
Journal:  J Clin Exp Neuropsychol       Date:  2009-10-29       Impact factor: 2.475

10.  Two decades of Huntington disease testing: patient's demographics and reproductive choices.

Authors:  Rebekah C Krukenberg; Daniel L Koller; David D Weaver; Jennifer N Dickerson; Kimberly A Quaid
Journal:  J Genet Couns       Date:  2013-05-25       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.